Virbac stock trades at EUR 312.50 versus EUR 311.50, plus 0.32 percent
Published on 09/30/2026 at 11:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Virbac (ISIN FR0000031577) was trading at EUR 312.50 at Lang & Schwarz on September 30, 2026 at 11:30 a.m. CEST, plus 0.32 percent versus the prior close of EUR 311.50 on September 29, 2026. On September 17, 2026, Virbac reported H1 figures that kept its full-year growth target at the upper end of the range.
H1 revenue reaches EUR 768.0 million
Revenue reached EUR 768.0 million in H1 2026, up 7.4 percent at constant exchange rates and scope from H1 2025. The companion animal segment grew 10.0 percent, while farm animal revenue increased 6.7 percent.
The revenue mix matters because Virbac is expanding across both of its main animal-health markets rather than relying on one product category. The company said its Supercharge platforms contributed to the performance, with Thyronorm strengthening its endocrinology business.
Adjusted EBIT margin widens to 18.8 percent
Adjusted EBIT rose to EUR 144.2 million from EUR 135.0 million in H1 2025, while the adjusted EBIT margin increased from 18.3 percent to 18.8 percent. Reuters reported the 6.8 percent rise in recurring operating profit and confirmed the upper end of Virbac's 2026 revenue outlook.
Net income increased 5.9 percent to EUR 87.1 million in H1 2026. Net debt was EUR 196.0 million at June 30, 2026, compared with EUR 173.0 million at December 31, 2025, reflecting seasonal working-capital needs and continued investment.
October 18 marks the next checkpoint
MarketScreener lists October 18, 2026, for Virbac's Q3 sales and revenue release. Until then, the key test is whether the H1 operating leverage can support the confirmed 2026 revenue growth range of 5.5 percent to 7.5 percent.
EUR 312.50 at Lang & Schwarz
Virbac stock was trading at EUR 312.50 at Lang & Schwarz on September 30, 2026 at 11:30 a.m. CEST, plus 0.32 percent versus the prior close of EUR 311.50 on September 29, 2026. The 52-week range was EUR 297.00 to EUR 389.50, placing the quote above the yearly low and below the yearly high.
Virbac stock facts
- Company: Virbac S.A.
- ISIN: FR0000031577
- Ticker: VIRP
- Primary exchange: Euronext Paris
- Price Lang & Schwarz (as of September 30, 2026, 11:30 a.m. CEST): EUR 312.50
- Change versus prior close: plus 0.32 percent
- Prior close Lang & Schwarz (September 29, 2026): EUR 311.50
- Market capitalization: EUR 2.6 billion (as of September 30, 2026)
- 52-week range: EUR 297.00-EUR 389.50 (as of September 30, 2026)
- Sector / Industry: Healthcare / Pharmaceuticals
- Next earnings date: October 18, 2026
